LBA02-04 NOVEL WEEKLY IMMUNOTHERAPY DOSING WITH AVELUMAB TOLERATED DURING BACILLUS CALMETTE-GUERIN INDUCTION THERAPY: INITIAL RESULTS OF THE ABC TRIAL

Michael S. Cookson,Abhishek Tripathi,Sanjay Patel,Daniel Zhao,Yuejin Wen,Riza Fabreo,Kelly G. Stratton

LBA02-04 NOVEL WEEKLY IMMUNOTHERAPY DOSING WITH AVELUMAB TOLERATED DURING BACILLUS CALMETTE-GUERIN INDUCTION THERAPY: INITIAL RESULTS OF THE ABC TRIAL

2021

Michael S. Cookson
Abhishek Tripathi
Sanjay Patel
Daniel Zhao
Yuejin Wen
Riza Fabreo
Kelly G. Stratton

INTRODUCTION AND OBJECTIVE:The optimal management of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) remains unclear. Given the limited treatment options, the...

Keywords:

Oncology
Avelumab
Bladder cancer
Medicine
Internal medicine
Immunotherapy
treatment options
bacillus
Dosing
optimal management
induction therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations